HMGCR antibody-associated myopathy in patient with endometrial cancer: a rare case.

Background: Anti-3-hydroxy-3-methylglutaryl coenzyme A reductase antibody (HMGCR antibody) antibody-associated myopathy is a rare disease. HMGCR antibody-associated myopathy in patient with endometrial cancer is extremely rare. Case Report: A 60-year-old woman without statin exposure presented with endometrial cancer Stage IIIC1 (T2N1M0) and HMGCR antibody-associated myopathy. After diagnosis, the patient received chemotherapy combining paclitaxel and carboplatin for endometrial cancer, and steroid and immunoglobulin for HMGCR antibody-associated myopathy. Two months after two cycles of chemotherapy, she died. Autopsy revealed that she died of HMGCR antibody-associated myopathy. Conclusion: In case of myopathy in patients with endometrial cancer, HMGCR antibody-associated myopathy should be considered. [ABSTRACT FROM AUTHOR]